AOD-9604 — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

AOD-9604

Also known as: AOD9604, Anti-Obesity Drug 9604, hGH fragment 177-191

Growth hormone fragment / lipolytic peptide

Research chemicalLast updated: November 4, 2026Based on 10 peer-reviewed studies

What it is

AOD-9604 is a peptide people use for fat loss and joint recovery. It mimics the fat-burning portion of growth hormone without the blood-sugar effects associated with GH itself. Not FDA-approved; banned by WADA; sold as a gray-market research compound.

The scientific side

AOD-9604 is a synthetic peptide consisting of the C-terminal fragment of human growth hormone (amino acids 177–191) with an additional tyrosine residue at the N-terminus. It is reported to mimic the lipolytic properties of growth hormone without diabetogenic side effects. In animal studies, both hGH and AOD9604 reduced body weight and body fat in obese mice following chronic intraperitoneal administration, correlating with increased expression of beta(3)-adrenergic receptor (beta3-AR) RNA — the major lipolytic receptor in fat cells. However, long-term treatment in beta3-AR knock-out mice failed to produce the body weight changes and lipolysis increase seen in wild-type mice, indicating the lipolytic actions are not mediated directly through beta3-AR, although both compounds increase beta3-AR expression, potentially contributing to enhanced lipolytic sensitivity over time. In an acute experiment, AOD9604 was capable of increasing energy expenditure and fat oxidation even in beta3-AR knock-out mice. A 2026 orthopaedics review lists AOD-9604 as promoting cartilage repair and lipolysis without IGF-1 stimulation. AOD-9604 does not influence the WADA hGH isoform immunoassay.

Class: Growth hormone fragment / lipolytic peptide

Administration & storage

Administration
Intraperitoneal (ip) injection — chronic administration in obese mice (PMID: 11713213)Intra-articular injection with ultrasound guidance — rabbit osteoarthritis model (PMID: 26275694)
Storage
For doping control purposes, -20°C was identified as the appropriate storage temperature for urine samples containing AOD-9604 and related peptides to maintain peptide stability.
Cautions
AOD-9604 is a non-approved compound; rigorous human safety data are scarce and there is potential for serious harm to patients.,AOD-9604 has been identified in confiscated vials and is available on internet websites, raising concerns about product purity, accurate labeling, and counterfeit preparations (PMID: 25208511, PMID: 24976118).,No clinical trial safety data are available in the reviewed literature beyond early Phase IIa trials noted as underway circa 2002; no results or adverse event data from those trials are described in these abstracts.,All efficacy and mechanism data currently derive from animal studies; extrapolation to human use is not supported by the reviewed literature (PMID: 41966639, PMID: 41490200).,Sterile technique is essential for any injectable compound to prevent contamination and infection risk.

Legal & regulatory status

US FDA

Not approved by US FDA; identified in confiscated vials in the USA and described as a non-approved compound operating in a 'gray market' (PMID: 41966639, PMID: 25208511)

WADA

Banned by the World Anti-Doping Agency (WADA); listed as a prohibited substance and subject to mandatory doping control screening (PMID: 25208511, PMID: 26578461)

Health Canada

Not stated in reviewed literature — requires manual verification